{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"groups":[{"description":"Induction: DPACE(dexamethasone,cisplatin,doxorubicin,cyclophosphamide,etoposide) chemotherapy plus stem cell collection. Additional stem cell collection and/or chemotherapy may be required.\n\nAfter collection, participants will receive dexamethasone x 4 days every 14 days.\n\nTransplant 1: The transplant preparative regimen will be bortezomib/thalidomide/dexamethasone/melphalan.\n\nOnce recovered, participants start thalidomide daily and dexamethasone x 4 days every 21 days.\n\nConsolidation (if administered): VDT-PACE(bortezomib,dexamethasone,thalidomide,cisplatin,doxorubicin,cyclophosphamide, etoposide) Transplant 2: 8 weeks to 6 months after the first transplant, participants will have the second transplant Maintenance: Year 1- VTD (bortezomib, thalidomide, dexamethasone) cycles. Year 2 - VCD (bortezomib, cyclophosphamide, dexamethasone)cycles.","id":"OG000","title":"Tandem Autologous Stem Cell Transplant"}],"populationDescription":"Data not available. Study conducted at University of Utah. Upon PI leaving Utah and coming to the University of Iowa, record NCT00670631 was transferred to Iowa by ClinicalTrials.gov staff. No research activities under NCT00670631 were conducted at Iowa. PRS staff at Iowa and Utah have corresponded and neither party (including PI) have the data.","reportingStatus":"POSTED","timeFrame":"Interim analyses for safety will be performed after 20, 100, 200, and 300 patients have been enrolled.","title":"In Assessing Patient Safety, we Will Examine Treatment Toxicity Related Mortality and SAEs. Historical Study Results Indicate That a Mortality Rate of Greater Than 10% is Not Acceptable in This Population, Nor is an SAE Rate of Greater Than 15%.","type":"PRIMARY"}